By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Prostate Cancer are discussed in a new report. According to news reporting out of Houston, Texas, by NewsRx editors, research stated, "SUMO-specific protease 1 (SENP1) is a member of de-SUMOylation protease family and has an important role in the regulation of androgen receptor-dependent transcription and hypoxia signaling. This activity profile of SENP1 prompted us to investigate whether SENP1 is involved in the pathogenesis of prostate cancer."
Our news journalists obtained a quote from the research from Texas Heart Institute, "In previous studies, we have detected the overexpression of SENP1 in both precancerous prostate intraepithelial neoplasia (PIN) lesions and prostate cancer tissue samples from patients. Whereas our whole-animal model has demonstrated that SENP1 induction is critical for prostate cell transformation, the role of SENP1 in prostate cancer progression is still unknown. In this study, we show that SENP1 expression directly correlates with prostate cancer aggressiveness and reccurrence, by analyzing more than 150 prostate cancer specimens. Modulating SENP1 level dictates colony formation of prostate cancer cell lines, tumor growth in nude mice and also prostate cancer cell migration and invasion. Silencing SENP1 level in highly metastatic prostate cancer cells perturbs their ability to metastasize to the bone and initiates secondary tumors. Mechanistically, the expression of two critical bone remodeling proteins, matrix metalloproteinase 2 (MMP2) and MMP9, is regulated by SENP1 through the HIF1 alpha signaling pathway."
According to the news editors, the research concluded: "All these results show the contribution of SENP1 to the progression of prostate cancer, and suggest that SENP1 may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients."
For more information on this research see: SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene, 2013;32(19):2493-2498. Oncogene can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Oncogene - www.nature.com/onc/)
Our news journalists report that additional information may be obtained by contacting Q. Wang, St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX, United States (see also Prostate Cancer).
Keywords for this news article include: Texas, Houston, Oncology, Protease, United States, Prostate Cancer, Cancer Gene Therapy, Prostatic Neoplasms, Enzymes and Coenzymes, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .